261 related articles for article (PubMed ID: 7973513)
1. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Sauter C
Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
[No Abstract] [Full Text] [Related]
2. [Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].
Cavalli F
Schweiz Med Wochenschr; 1994 Oct; 124(43):1882-4. PubMed ID: 7973514
[No Abstract] [Full Text] [Related]
3. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
4. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
5. The use of adjuvant chemotherapy for breast cancer in a community practice.
Rosenberg A; Winer EP; Cadman E
Conn Med; 1985 May; 49(5):281-5. PubMed ID: 3839177
[No Abstract] [Full Text] [Related]
6. Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer.
Coccaro M; Gallucci G
J Clin Oncol; 2008 Jul; 26(19):3288; author reply 3289. PubMed ID: 18591567
[No Abstract] [Full Text] [Related]
7. [Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients].
Toi M; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1994 Sep; 21(12):2057-60. PubMed ID: 8085859
[No Abstract] [Full Text] [Related]
8. Clinical trials referral resource. Adjuvant therapy of breast cancer.
Cheson BD
Oncology (Williston Park); 1989 Jun; 3(6):70-1, 74-5, 78. PubMed ID: 2534915
[No Abstract] [Full Text] [Related]
9. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
10. [Compliance in adjuvant chemotherapy].
Michel U; Schwarz R; Kaufmann M
Rehabilitation (Stuttg); 1986 Feb; 25(1):17-23. PubMed ID: 3754346
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].
Pribylová O; Petruzelka L; Honová H; Fischer J; Bustová I; Siffnerová H; Kůta M; Miller V; Hacklová M; Machácek J; Kohoutek M; Vodvárka P; Kyselá T; Tajblová J; Suk J; Dorazilová V; Bauer J
Sb Lek; 1998; 99(1):25-31. PubMed ID: 9748796
[TBL] [Abstract][Full Text] [Related]
12. Alternating versus sequential therapy in advanced breast cancer.
Romero A; Rabinovich MG; Pérez JE; Macchiavelli M; Leone BA; Strauss E; Goldar D; Alvarez LA; Vallejo C
Medicina (B Aires); 1987; 47(3):243-8. PubMed ID: 3326994
[No Abstract] [Full Text] [Related]
13. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
Jurga L; Misurová E; Vancík J
Neoplasma; 1993; 40(4):259-62. PubMed ID: 8272153
[No Abstract] [Full Text] [Related]
14. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
[TBL] [Abstract][Full Text] [Related]
15. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant therapy of breast cancer. 1: Cytostatic therapy].
Possinger K; Sauer HJ; Wilmanns W
Fortschr Med; 1986 Aug; 104(29):552-5. PubMed ID: 3758881
[No Abstract] [Full Text] [Related]
17. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
18. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Panasci LC
J Clin Oncol; 2006 May; 24(15):2392; author reply 2392. PubMed ID: 16710042
[No Abstract] [Full Text] [Related]
19. [Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
Chen JA
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):202-4. PubMed ID: 8261866
[TBL] [Abstract][Full Text] [Related]
20. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]